Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it ...
EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 ...
The International Association of Top Professionals (IAOTP) will honor Dr. Kerriann Greenhalgh at their annual awards ...
CHONGYANG CITY, HUBEI PROVINCE, CHINA, February 9, 2026 /EINPresswire.com/ -- The global packaging industry stands at a ...
The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...
WOBURN, MA, UNITED STATES, February 9, 2026 /EINPresswire.com/ -- Powered by AFA‑enabled workflows that deliver ...
Company and CoSara believe that ISO certification is a critical component of the regulatory requirements for clearance of new platform ...
In areas where the nearest emergency room is far away, how can responders give patients the best possible care when time is ...
The Commerce Commission has published a statement of issues relating to an application from Rafting JV Co seeking clearance to acquire the rafting and sledging assets of Rotorua Rafting, Kaitiaki ...
FOSHAN, GUANGDONG, CHINA, January 26, 2026 /EINPresswire.com/ -- The global industrial landscape is experiencing a ...
Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results